Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4FF6

Mycobacterium tuberculosis DprE1 in complex with CT325 - monoclinic crystal form

4FF6 の概要
エントリーDOI10.2210/pdb4ff6/pdb
関連するPDBエントリー4FDN 4FDO 4FDP 4FEH
分子名称Probable decaprenylphosphoryl-beta-D-ribose oxidase, FLAVIN-ADENINE DINUCLEOTIDE, 3-(hydroxyamino)-N-[(1R)-1-phenylethyl]-5-(trifluoromethyl)benzamide, ... (5 entities in total)
機能のキーワードalpha+beta, oxidoreductase, decaprenylphosphoryl-beta-d-ribose, oxidoreductase-oxidoreductase inhibitor complex, oxidoreductase/oxidoreductase inhibitor
由来する生物種Mycobacterium tuberculosis
タンパク質・核酸の鎖数2
化学式量合計107209.62
構造登録者
Batt, S.M.,Besra, G.S.,Futterer, K. (登録日: 2012-05-31, 公開日: 2012-07-04, 最終更新日: 2024-11-20)
主引用文献Batt, S.M.,Jabeen, T.,Bhowruth, V.,Quill, L.,Lund, P.A.,Eggeling, L.,Alderwick, L.J.,Futterer, K.,Besra, G.S.
Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors.
Proc.Natl.Acad.Sci.USA, 109:11354-11359, 2012
Cited by
PubMed Abstract: Resistance against currently used antitubercular therapeutics increasingly undermines efforts to contain the worldwide tuberculosis (TB) epidemic. Recently, benzothiazinone (BTZ) inhibitors have shown nanomolar potency against both drug-susceptible and multidrug-resistant strains of the tubercle bacillus. However, their proposed mode of action is lacking structural evidence. We report here the crystal structure of the BTZ target, FAD-containing oxidoreductase Mycobacterium tuberculosis DprE1, which is essential for viability. Different crystal forms of ligand-free DprE1 reveal considerable levels of structural flexibility of two surface loops that seem to govern accessibility of the active site. Structures of complexes with the BTZ-derived nitroso derivative CT325 reveal the mode of inhibitor binding, which includes a covalent link to conserved Cys387, and reveal a trifluoromethyl group as a second key determinant of interaction with the enzyme. Surprisingly, we find that a noncovalent complex was formed between DprE1 and CT319, which is structurally identical to CT325 except for an inert nitro group replacing the reactive nitroso group. This demonstrates that binding of BTZ-class inhibitors to DprE1 is not strictly dependent on formation of the covalent link to Cys387. On the basis of the structural and activity data, we propose that the complex of DrpE1 bound to CT325 is a representative of the BTZ-target complex. These results mark a significant step forward in the characterization of a key TB drug target.
PubMed: 22733761
DOI: 10.1073/pnas.1205735109
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.6 Å)
構造検証レポート
Validation report summary of 4ff6
検証レポート(詳細版)ダウンロードをダウンロード

234136

件を2025-04-02に公開中

PDB statisticsPDBj update infoContact PDBjnumon